EVALUATION OF COVID MORTALITY DURING HOSPITAL ADMISSION IN PATIENTS RECEIVING ONCOLOGIC TREATMENT
6ER-018
USE OF ELTROMBOPAG IN ROUTINE CLINICAL PRACTICE
6ER-014
ANALYSIS OF THE EVOLUTION OF INTERLEUKIN-6 IN COVID-19 PATIENTS AFTER BEING TREATED WITH DEXAMETHASONE
6ER-013
ANALYSIS OF PATIENTS’ MORTALITY IN SARS-COV-2 INFECTION DURING THE FIRST MONTH OF HOSPITAL ADMISSION
6ER-012
EFFECTIVENESS OF IL-23 INHIBITORS IN PATIENTS WITH MODERATE–SEVERE CHRONIC PLAQUE PSORIASIS
6ER-011
COTRIMOXAZOL: HOW FOLATE SUPPLEMENTATION COULD AFFECT TREATMENT EFFICACY
6ER-008
DEVELOPMENT OF A RISK-SHARING MODEL BASED ON THE CLINICAL PERFORMANCE OF ONASEMNOGENE ABEPARVOVEC (ZOLGENSMA)
6ER-007
REAL-WORLD EFFECTIVENESS OF GENE THERAPY ONASEMNOGENE ABEPARVOVEC (ZOLGENSMA) FOR SPINAL MUSCULAR ATROPHY: A REVIEW
6ER-006
PARACETAMOL VERSUS IBUPROFEN FOR TREATMENT OF PERSISTENT DUCTUS ARTERIOSUS CLOSURE IN PRETERM INFANTS: IBUPAR-TRIAL
6ER-002
Applying reflective Multicriteria Decision Analysis to understand the value of therapeutic alternatives in the management of anaemia in gynaecologic surgery
6ER-001
CAN PHARMACISTS IMPROVE THEIR PATIENT COMMUNICATION BY READING FICTION?
6ER-037
DRUG - DRUG INTERACTIONS WITH QT PROLONGING DRUGS IN PATIENTS ADMITTED TO A CARDIOVASCULAR DEPARTMENT: A RETROSPECTIVE ANALYSIS
6ER-036
DEPRESCRIBING TOOLS FOR THE ELDERLY: A SYSTEMATIC REVIEW
6ER-035
AN EVALUATION OF HEALTH PROMOTION AND DISEASE PREVENTION KNOWLEDGE IN PATIENTS ATTENDING A HOSPITAL OUTPATIENT PHARMACY
6ER-034
MEDICATION DEPRESCRIBING AND FOLLOW-UP: A SURVEY AMONG SUBACUTE MULTIMORBID PATIENTS IN A MULTIDISCIPLINARY OUTPATIENT CLINIC
